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ABSTRACT  44 
 45 
BACKGROUND. Although combined antiretroviral therapy (cART) has saved millions of lives, it 46 
is incapable of full immune reconstitution and virus eradication. The Transactivator of transcription 47 
(Tat) protein is a key human immunodeficiency virus (HIV) virulence factor required for virus 48 
replication and transmission. Tat is expressed and released extracellularly by infected cells also 49 
under cART and in this form induces immune dysregulation, and promotes virus reactivation, entry 50 
and spreading. Of note, anti-Tat antibodies are rare in natural infection and, when present, correlate 51 
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with asymptomatic state and reduced disease progression. This suggested that induction of anti-Tat 52 
antibodies represents a pathogenesis-driven intervention to block progression and to intensify 53 
cART. Indeed Tat-based vaccination was safe, immunogenic and capable of immune restoration in 54 
an open-label, randomized phase II clinical trial conducted in 168 cART-treated volunteers in Italy. 55 
To assess whether B-clade Tat immunization would be effective also in patients with different 56 
genetic background and infecting virus, a phase II trial was conducted in South Africa. 57 
METHODS. The ISS T-003 was a 48-week randomised, double-blinded, placebo-controlled trial to 58 
evaluate immunogenicity (primary endpoint) and safety (secondary endpoint) of B-clade Tat (30 59 
μg) given intradermally, 3 times at 4-week intervals, in 200 HIV-infected adults on effective cART 60 
(randomised 1:1) with CD4+ T-cell counts ≥200 cells/µL. Study outcomes also included cross-clade 61 
anti-Tat antibodies, neutralization, CD4+ T-cell counts and therapy compliance. 62 
RESULTS. Immunization was safe and well-tolerated and induced durable, high titers anti-Tat B-63 
clade antibodies in 97% vaccinees. Anti-Tat antibodies were cross-clade (all vaccinees tested) and 64 
neutralized Tat-mediated entry of oligomeric B-clade and C-clade Envelope (Env) in dendritic cells 65 
(24 participants tested). Anti-Tat antibody titers correlated positively with neutralization. Tat 66 
vaccination increased CD4+ T-cell numbers (all participants tested), particularly when baseline 67 
levels were still low after years of therapy, and this had a positive correlation with HIV 68 
neutralization. Finally, in cART non-compliant patients (24 participants), vaccination contained 69 
viral load rebound and maintained CD4+ T-cell numbers over study entry levels as compared to 70 
placebo. 71 
CONCLUSIONS. The data indicate that Tat vaccination can restore the immune system and 72 
induces cross-clade neutralizing anti-Tat antibodies in patients with different genetic backgrounds 73 
and infecting viruses, supporting the conduct of phase III studies in South Africa. 74 
TRIAL REGISTRATION. ClinicalTrials.gov NCT01513135, 01/23/2012. 75 
KEY WORDS: Tat, HIV, AIDS, clinical trials, vaccine, cross-clade antibodies, neutralization, 76 
CD4+ T cells, cART, therapy intensification. 77 
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 78 
BACKGROUND  79 
South Africa is severely affected by human immunodeficiency virus (HIV) infection (1). The HIV 80 
counselling and testing campaign (HCT) launched by the National Department of Health has 81 
steadily increased the proportion of HIV-infected patients on combined antiretroviral therapy 82 
(cART). However, access to therapy and care of millions of people living with HIV is posing an 83 
enormous challenge to the public health system by means of a growing work overload and 84 
economic burden. This is going to be further complicated by the expected implementation of the 85 
new World Health Organization (WHO) guidelines that recommend starting therapy at the time of 86 
the first positive HIV testing ("test and treat") (2). However, despite vast access to cART, the rates 87 
of HIV morbidity/mortality are still high, with a 14% annual increase of HIV drug resistance related 88 
to insufficient treatment compliance, which hampers an effective suppression of virus replication, a 89 
prerequisite to reduce virus transmission (3). Further, late therapy initiation is still frequent in South 90 
Africa limiting the extent of CD4+ T cell recovery and immune restoration (4,5). Similarly, 91 
persistent immune activation, particularly when associated with poor immunological response to 92 
therapy, leads to disease progression even under HIV suppression (6-8). These are causes of 93 
increasing co-morbidities, hospitalization, deaths and costs for the National Health Systems. In this 94 
context, an effective therapeutic vaccine, in conjunction with existing strategies, may represent a 95 
relevant, cost-effective intervention to intensify cART (9).  96 
The Transactivator of transcription (Tat) is a key HIV virulence factor playing pivotal roles in virus 97 
gene expression, replication, transmission and disease progression (reviewed in 10 and 11). Tat is 98 
produced very early upon infection (12-16) and continues to be expressed under cART (17, 18), is 99 
released extracellularly (19-21), accumulates in tissues (22, 23), and exerts effects on both the virus 100 
and the immune system (17, 24-52) that make it an optimal candidate for therapeutic immunization 101 
and cART intensification (53-58). In particular, by promoting an excessive and improper immune 102 
stimulation, Tat prepares target cells for virus propagation, while disabling an effective immune 103 
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control (17, 24-52). This leads to the chronic loss of immune homeostasis observed in HIV-infected 104 
patients, which is only partially reverted by cART (59-63). Further, extracellular Tat, which is 105 
present on virions (64), binds the Envelope (Env) spikes forming a virus entry complex that favors 106 
infection of dendritic cell (DC) and T cells, key components of the virus reservoir (65). Of note, by 107 
binding the Env C-C chemokine receptor 5 (CCR5) co-receptor binding sites, Tat shields Env from 108 
anti-HIV antibodies (Abs), thus inhibiting virus neutralization, which, however, is restored by anti-109 
Tat Abs (65). Notably, anti-Tat Abs are uncommon in natural infection and, when present, correlate 110 
with the asymptomatic state, higher CD4+ T-cell number, lower viral load, and reduced disease 111 
progression (66-70). This suggested that the induction of effective anti-Tat Abs represents a 112 
pathogenesis-driven intervention to block progression and to intensify cART efficacy.  113 
After completion of randomised, placebo-controlled, double-blinded phase I trials with the 114 
biologically active HIV-1 B-clade Tat protein in HIV-infected and uninfected individuals in Italy 115 
(54-56), an open-label randomised exploratory phase II trial with Tat was conducted in 168 HIV-116 
infected anti-Tat Abs negative, virologically suppressed cART-treated (mean of 6 years) adult 117 
subjects in Italy (ISS T-002, ClinicalTrials.gov NCT00751595) (53, 57). The endpoints were to 118 
evaluate immunogenicity and safety of B-clade Tat protein administered at 7.5 or 30 µg, given 3 or 119 
5 times monthly, and to investigate immunological and virological disease biomarkers. The vaccine 120 
was safe and well tolerated and induced anti-Tat Abs in most patients (79%), with the highest 121 
frequency and durability in the Tat 30 µg groups (89%), particularly when given 3 times (92%). 122 
Vaccination promoted a durable and significant restoration of T, B, and natural killer (NK) cell 123 
numbers, increased CD4+ and CD8+ central memory subsets, and upregulated the expression of 124 
human leukocyte antigen-D related (HLA-DR+) on CD8+ killer T cells, a phenotype found to be 125 
increased in elite controllers and to contribute to HIV containment (71, 72). Moreover, a significant 126 
reduction of blood proviral DNA was seen after 3 years from the first immunisation, particularly 127 
under protease inhibitor (PI)-based regimens and with Tat 30 µg given 3 times (30 μg, 3x), reaching 128 
a predicted 70% decay with a half-life of 88 weeks (57). This decay was significantly associated 129 
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with anti-Tat immunoglobulin (Ig) M and IgG Ab titers and neutralization of Tat-mediated entry of 130 
oligomeric Env in DC. Neutralization predicted HIV-1 DNA decay (57). 131 
Based on these data, a 48-week randomised, double-blinded, placebo-controlled phase II study was 132 
conducted in cART-treated South African adult volunteers to verify the immunogenicity and safety 133 
of the B-clade Tat vaccine in a population with a different genetic background and mainly infected 134 
with a C clade virus. Anti-Tat Abs were further characterised to explore cross-clade recognition and 135 
their capability of cross-neutralising Tat-mediated oligomeric Env entry in DC. CD4+ T-cell counts 136 
were monitored for the entire trial, and the relationship between neutralization and CD4+ T-cell 137 
counts, as well as between anti-Tat and anti-Env Ab titers and neutralization, were also examined. 138 
 139 
Methods 140 
Production and purification of the recombinant biologically active HIV-1 Tat protein for human 141 
use. The biologically active recombinant clade B HIV-1 Tat, selected as vaccine candidate for 142 
human use, is the 86 amino acid-long protein derived from the HTLV-IIIB strain (BH-10 clone) 143 
(Supplementary Figure 1). The protein was produced under Good Manufacturing Practice (GMP) 144 
conditions by Diatheva-Avitech APU Srl, Fano (PU), Italy. Tat vialing, packaging and batch release 145 
was performed by Injectalia Srl, Rome, Italy. Briefly, the Tat protein is obtained from a lysate of E. 146 
coli cells engineered with the pET-tat plasmid, constructed for Tat expression. The pET system is 147 
based on the T7 promoter-driven system originally developed by Studier and colleagues (73-75), 148 
and provides vector-host combinations that enable tuning of basal expression levels to optimize 149 
target gene expression (75). The GMP protein is then purified by diethylaminoethyl (DEAE) 150 
chromatography followed by heparin sepharose chromatography. Following purification, the Tat 151 
protein is formulated in potassium phosphate saline buffer, pH 7.4, containing 1% sucrose and 1% 152 
human serum albumin (HSA). This formulation was defined in order to maintain the biological 153 
activity of the protein in a liquid form, stored at -80 °C in the absence of light over 3 years. 154 
 155 
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Study design and conduction. The ISS T-003 (ClinicalTrials.gov NCT01513135) was a phase II, 156 
randomised, double-blinded, placebo-controlled, clinical trial with the recombinant biologically 157 
active HIV-1 B-clade Tat protein conducted at the MeCRU, University of Limpopo, Medunsa 158 
Campus (now Sefako Makgatho Health Sciences University), South Africa (ISS T-003 Study 159 
Protocol, Supplementary Material). The study was designed to evaluate Tat protein immunogenicity 160 
and safety in HIV-1-infected, cART-treated, anti-Tat Ab-negative adult South Africans, and to 161 
explore CD4+ T-cell numbers and anti-Tat cross-clade neutralizing activity after immunization. The 162 
study duration was 48 weeks including an 8-week treatment phase and a 40-week follow-up phase. 163 
The allowed window for patients’ screening was 35 days long. 164 
Patients were recruited at the public Health Facilities located in the MeCRU catchment area 165 
(Tshwane District). Patients received cART at the Health Facilities throughout the trial. Procedures 166 
for patients' recruitment, access to medical records, referral to the Health Facilities for intervening 167 
medical conditions were implemented under the coordination of the South African National 168 
Department of Health and the Department of Health of the Gauteng Province, South Africa. A 169 
community involvement program was implemented at MeCRU with the support of the South Africa   170 
AIDS Vaccine Initiative, a lead program of the South Africa Medical Research Council. MeCRU 171 
and local community advisory board and groups implemented community education strategies on 172 
HIV/AIDS awareness, participation in clinical trials, recruitment and retention strategies. A 173 
Contract Research Organization monitored study conduct, data quality and performed safety data 174 
analyses, which were periodically evaluated by the Local Medical Monitor and Data Safety 175 
Monitoring Board. The Local Medical Monitor was a blinded sponsor’s representative expert in 176 
HIV/AIDS clinical management. He reviewed safety data, assisted the Investigator in assessing 177 
adverse events (AEs) severity and causality, and forwarded quarterly reports to the Data Safety 178 
Monitoring Board. Data Safety Update Reports were submitted to the Competent Authorities as 179 
required.  180 
 181 
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Endpoints. The primary endpoint of the study (immunogenicity) was measured by the induction, 182 
magnitude and persistence of anti-Tat IgM, IgG and IgA in sera. The secondary endpoint (safety) 183 
was assessed by collecting all AEs during the trial, which included vital signs and any clinically 184 
significant change in haematological, biochemical and coagulation parameters. All the recorded 185 
AEs were classified according to Medical Dictionary for Regulatory Activities (MedDRA) 186 
preferred terms and system organ class, and on the basis of drug relationship and grade of severity. 187 
 188 
Study participants. Two hundred adult cART-treated patients were recruited and randomised 1:1 to 189 
receive Tat vaccine or placebo. Main criteria for enrolment were the following: age 18-45 years 190 
(inclusive), current cART-treatment and chronically suppressed HIV-1 infection as indicated by a 191 
HIV-1 plasma viremia <400 copies/mL and a CD4+ T-cell count ≥200 cells/µL at screening, and 192 
documented at least once during the 12-month period prior to screening irrespective of the pre-193 
cART CD4+ nadir, B-clade anti-Tat Ab-negative, willingness and ability to provide informed 194 
consent, and no acute illness at study start. Female participants of childbearing potential were 195 
required to have a negative pregnancy test at screening and immediately before each vaccination 196 
and to use an acceptable method of contraception for at least 3 weeks prior to the first vaccination 197 
and for all duration of the trial. 198 
 199 
Study procedures. All participants were randomized to receive the Tat vaccine (30 μg dose) or 200 
placebo (vaccine formulation buffer), administered intradermally 3 times at 4-week intervals (ISS 201 
T-003 Study Protocol, Supplementary Material). Randomisation was performed in block sizes of 202 
four. Participants were allocated to a randomisation number consisting of a 3-digit sequential 203 
number pre-fixed by a 1-digit unique site identifier. Upon screening completion and immediately 204 
prior to vaccine administration, volunteers were randomly assigned to the next available treatment 205 
number according to the randomisation schedule, which was generated by the Contract Research 206 
Organization using the SAS® procedure PROC PLAN with a randomisation ratio of 1:1. 207 
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Participants and clinical and laboratory staff, project management personnel and anyone involved in 208 
data management or analysis and the sponsor were blinded to treatment assignment. Each 209 
investigational product (Tat vaccine/placebo) vial was packaged in one kit-box constituted of three 210 
vials with the same label for vaccine or placebo, according to the “Guide to Good Manufacturing 211 
Practice for Medicines in South Africa, Version 4.01 March 2009”. Kits were provided to the 212 
clinical site in a blinded fashion by the sponsor. 213 
The evaluations performed at each of the 12 study visits varied according to the schedule provided 214 
in the supplementary material (ISS T-003 Study Protocol). General laboratory assessments, 215 
including CD4+ T-cell number and HIV plasma viral load were performed by a centralized 216 
laboratory (South African National Health Laboratory Service at the Dr. George Mukhari, Ga-217 
Rankuwa, Pretoria). CD4+ T-cell counts were performed according to standard national laboratory 218 
measurements. HIV-1 viral load was determined with the Abbott Real Time HIV-1 assay (lower 219 
limit of detection 40 RNA copies/mL). Blood samples were collected and transferred according to 220 
protocol-specific procedures, and tested within 3 hours from sample withdrawal. Anti-Tat binding 221 
and neutralizing Abs were assessed on cryopreserved specimens shipped by a certified courier to 222 
the designated Core Laboratory (Core Laboratory of Immunology and Virology, San Gallicano 223 
Institute, Istituti Fisioterapici Ospitalieri, Rome, Italy) according to Standard Operating Procedures. 224 
 225 
Measurement of serum Abs against Tat proteins. The Tat proteins used for anti-Tat Ab 226 
determination and for anti-Tat Ab cross-clade analysis were, respectively, from HIV-1 B clade 227 
(GenBank accession n.: AAA44199.1); C clade (GenBank accession n.: AAL06113.1); A clade 228 
(GenBank accession n.: AAP33775.1);  D clade (GenBank accession n.: AAP33758.1) (amino acid 229 
sequences are shown in Supplementary Figure 1) and were purchased from Diatheva. All proteins 230 
were biologically active as determined by the rescue assay with HLM-1 cell line carrying a Tat-231 
defective HIV provirus (19, 20), and/or by Tat uptake by monocyte-derived DC (MDDC) evaluated 232 
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by intracellular staining for Tat in flow cytometry (35), a potency test that is used to release the Tat 233 
vaccine clinical lots. 234 
Serum IgM, IgA and IgG against B-, A-, C-, and D-clade Tat were assessed by enzyme-linked 235 
immunosorbent assay (ELISA), as previously described (76). Briefly, 96-well microplates (Nunc-236 
Immuno Plate MaxiSorp Surface; Nunc) were coated with Tat (100 ng/well) in 200 µL of 0.05 237 
mol/L carbonate-buffer (pH 9.6), and incubated overnight at 4°C. Wells were washed 5 times with 238 
phosphate-buffered solution (PBS), pH 7.4, containing 0.05% Tween-20, by an automatic plate 239 
washer (Asys Hitech flexi wash). Wells were then saturated with PBS containing 1% bovine serum 240 
albumin (BSA) and 0.05% Tween-20 (Sigma) (blocking buffer) for 90 min at 37 °C and then 241 
washed again as above. One hundred µL of patient serum samples [diluted at 1:100 (for anti-Tat 242 
IgG) or at 1:25 (for anti-Tat IgM or IgA detection) in blocking buffer] were added to the wells and 243 
incubated at 37 °C for 90 min. To correct for unspecific binding, each sample was assessed in 244 
duplicate against Tat and singly against the buffer in which Tat had been re-suspended. After 245 
washing, wells were saturated again with blocking buffer for 15 min at 37 °C, washed again and 246 
then a goat anti-human IgG, IgM, or IgA horseradish peroxidase-conjugated secondary Ab (100 247 
µL/well) (PIERCE-Thermo Scientific) was added to each well, and incubated for an additional 90 248 
min at 37 °C. Antigen-bound Abs were revealed by the addition of ABTS [2,2'-azino-bis(3-249 
ethylbenzothiazoline-6-sulphonic acid)] solution (Roche Diagnostics) for 60 min at 37 °C. 250 
Absorbance was measured at 405 nm using a microplate reader (BIO-TEK Instruments EL800). 251 
The assay was considered valid only when both the positive and negative controls were within 252 
±10% of variation of the absorbance values recorded in previous 50 assays. For the cut-off 253 
calculation, both the optical density (OD) readings at 405 nm of the wells coated with Tat and the 254 
delta (Δ) value were utilized. The Δ value was obtained by subtracting the OD reading of the well 255 
coated with the buffer alone from the average of the OD values of the two wells coated with the Tat 256 
protein. Serum samples were considered positive when both the sample OD at 405 nm and Δ values 257 
were ≥0.350 and ≥0.150, respectively. The 0.350 and 0.150 OD values had been previously 258 
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calculated as 3 standard deviations (99% confidence interval) above the mean of each of the 259 
absolute and Δ OD values obtained with sera from 89 Italian HIV-negative blood donors and 34 260 
South African HIV-negative individuals. If the sample scored positive, the titer value was 100 for 261 
IgG, 25 for IgM and IgA. However, if the OD reading of the sample exceeded both the absolute and 262 
Δ OD values by 50%, serial two-fold dilutions of the sample were performed to determine the 263 
endpoint titers. Endpoint titers were determined as the reciprocal of the last sample dilution that still 264 
had ≥0.350 and ≥0.150 OD values for absolute and Δ parameters. For Tat cross-clade analysis, OD 265 
values obtained with the different proteins in the same ELISA test, on the same sample, at the same 266 
dilution, were compared.  267 
 268 
Measurement of serum Abs against the Env protein. The same ELISA protocol and criteria for cut-269 
off determination were applied for measurement of anti-Env Abs and their titer definition (70). The 270 
ΔV2-Env (Novartis Vaccine & Diagnostics) from the HIV-1 C-clade TV1 strain was used. Only 271 
IgG Abs were tested, starting from a 1:100 dilution.  272 
 273 
Anti-Tat neutralizing Ab responses. Anti-Tat neutralizing activity in sera was assessed by Tat-274 
mediated Env entry in DC as described (35). Briefly, MDDC from blood of healthy donors were 275 
cultured and induced to maturation as described (35, 36). Purity of  MDDC was always ≥99%. Sera 276 
were diluted 1:30 in PBS and incubated for 60 min at 37 °C with B- or C-clade trimeric Env (0.4 277 
μM in monomer) (Novartis) previously mixed for 10 min at 25 °C with B- or C-clade Tat (0.4 μM) 278 
or degassed PBS (control). Samples were then added to MDDC (2x105 cells/mL) to a 1:5 final 279 
dilution and incubated for 10 min at 37 °C. Cells were then washed with cold medium and treated 280 
for 10 min at 37 °C with ethylene diamine tetra-acetic acid (EDTA) (Life Technologies) to remove 281 
any externally bound protein. After fixation and permeabilization, DC were stained with rabbit anti-282 
gp120 polyclonal Abs (Chem Progress) or purified rabbit-IgG control Abs (Sigma-Aldrich), 283 
followed by fluorescein isothiocyanate (FITC)-conjugated anti-rabbit Ig (Pierce). Fluorescence was 284 
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measured by flow cytometry and results expressed as the percentage of Env-positive cells as 285 
compared to isotype-stained samples. Sera were defined as “neutralizing” when capable of 286 
inhibiting Env entry into DC in the presence of Tat by at least 50% as compared to baseline sera 287 
values (ND50). 288 
 289 
Sample size calculation. Sample size for this study was powered for immunogenicity evaluation. 290 
The immunogenicity was assumed to be 80% for vaccinees and 60% for placebos, with alpha set at 291 
0.05 (2-tailed). According to this assumption, a sample size of 91 per group had 80% power of 292 
showing statistical significance (p<0.05). The assumed response rate for vaccinees was based on the 293 
results of studies conducted at the time of protocol preparation. The response rate in placebos was 294 
set in the absence of reference-controlled studies and was therefore very conservative. The actual 295 
power of the study, given the percentage of spontaneous seroconversion, is 99%. 296 
 297 
Statistics. Two populations were considered for statistical analyses: the immunogenicity population 298 
(199 subjects), representing all randomised individuals who received at least 2 immunizations, and 299 
the safety population (200 subjects), representing all randomised subjects who received at least one 300 
immunization. Subjects with at least one positive anti-Tat Ab response at any given time point 301 
during the study were defined as “responders”. Ninety-five % confidence intervals were estimated 302 
for the primary endpoints; comparison between treatment groups was performed using the Chi-303 
Square test. Kaplan-Meier method was used to assess the cumulative probability of anti-Tat Ab 304 
persistence, by treatment groups, and compared by the Log-Rank test. Anti-Tat Ab titers and the 305 
percentage of DC internalizing Env were compared between vaccinees and placebos by the 306 
Student’s t-test after log10 transformation to normalize the data distribution. Wilcoxon signed-rank 307 
test was used to assess the intensity of cross-clade anti-Tat Abs (measured as OD units) after 308 
immunization. Longitudinal analysis for repeated measures was applied for analysis of CD4+ T-cell 309 
number, after controlling normality assumption of variable distribution (Saphiro-Wilk test). The 310 
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relationship between Tat-mediated Env entry in DC and anti-Tat or anti-Env Ab-binding titers or 311 
CD4+ T-cell number was assessed by the longitudinal regression model using the generalized 312 
estimating equations method. Wilcoxon signed-rank test was used to assess changes from baseline 313 
of CD4+ T-cell number in subjects not compliant to cART, while Wilcoxon-Mann-Whitney test was 314 
performed in order to evaluate differences between non-CART-compliant vaccinees and placebos at 315 
each visit. Statistical analyses were carried out at two-sided with a 0.05 significance level, using 316 
SAS (Version 9.2, SAS Institute Inc., Cary, NC, USA). 317 
 318 
Ethics. The ISS T-003 was authorized by the South Africa Medicines Control Council and the 319 
Sefako Makgatho University Research Ethics Committee (approval number: MREC/P/221/2010). 320 
The study was conducted in accordance with the current Declaration of Helsinki and International 321 
Conference on Harmonization Good Clinical Practice guidelines. 322 
Patients gave written approval to perform the study-specific procedures, including access to source 323 
medical data (demography, diagnosis, cART compliance). 324 
 325 
Results 326 
Patients accrual and demographic data. Seven-hundred-seventy cART-treated patients were 327 
assessed for eligibility (Figure 1). Two hundred participants were enrolled between February 27, 328 
2012 and 13 June, 2013. Study was completed in June 2014. Participants were randomised 1:1 to 329 
one of the two treatment groups. Ninety-seven percent of enrolled participants completed the study. 330 
All individuals were analyzed for safety. One subject who received only one immunization was 331 
excluded from the immunogenicity population (Figure 1). Thirteen volunteers were excluded from 332 
the “Per Protocol” analysis for major protocol non-compliance (Figure 1). Baseline demographic 333 
and clinical characteristics of participants are shown in Table 1. Twenty-six percent of participants 334 
were male and 74% female; all were black, except one volunteer. At the study entry the mean age 335 
was 36 years for both vaccinees and placebos. In vaccinees, the mean CD4+ T-cell count was 510 336 
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cells/µL, 95% of them had undetectable HIV RNA, the mean years from HIV diagnosis was 5.0, 337 
while the mean time on cART was 3.5 years, with 97% on non-nucleoside reverse-transcriptase 338 
inhibitors (NNRTI) or nucleoside reverse transcriptase inhibitors (NRTI)-based and 3% on PI-based 339 
regimens. In placebos, the mean CD4+ T-cell count was 563 cells/µL, HIV RNA was undetectable 340 
in 96% of them, the mean years from HIV diagnosis was 4.9 years, while the mean time on cART 341 
was 3.3, with 98% on NNRTI or NRTI-based and 2% on PI-based regimens. 342 
 343 
HIV-1 B-clade Tat vaccine safety and tolerability. Tat immunization was safe and well tolerated 344 
without relevant differences between vaccinees and placebos. In particular, 190 patients (96 345 
vaccinees and 94 placebos) experienced at least one AE during the study, mainly of mild intensity 346 
(Table 2). General disorders and administration site conditions were the most frequent AEs related 347 
to study treatment both in vaccinees (73%) and placebos (58%), followed by nervous system 348 
disorders (mainly headache events), which had higher incidence in placebos (38%) than vaccinees 349 
(27%) (Table 3). No serious AEs (SAE) related to study treatment or suspected unexpected adverse 350 
reactions were reported. The non-serious AEs related to study drug were mostly mild and local. 351 
Most clinically relevant abnormal laboratory events were reported with a similar frequency in both 352 
the treatment groups and were considered unrelated, since they are findings typically associated 353 
with HIV-1 infection (i.e. low haemoglobin, low neutrophil and white cell counts, increased viral 354 
load). Eight participants (2 placebos and 6 vaccinees) reported at least one SAE (unrelated to study 355 
treatment). In particular, 1 placebo underwent hysterectomy and 1 was diagnosed with type-II 356 
diabetes mellitus. Among the vaccinees, 2 participants were diagnosed with pulmonary 357 
tuberculosis, 1 patient was admitted to the hospital for respiratory tract infection, bronchiectasis-358 
empyema thoracis and abdominal pain, 1 patient underwent hysterectomy, and intentional self-359 
injury was reported in 2 participants. All these SAE resolved completely, except the type II diabetes 360 
mellitus. 361 
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Since no “important safety events” or “significant findings” emerged during the study, the Data 362 
Safety Monitoring Board concluded that the Tat vaccine is safe and well tolerated. 363 
 364 
HIV-1 B-clade Tat vaccine induces durable anti-Tat Abs of all subclasses. Tat immunization 365 
induced anti-Tat B-clade Abs in 97% of vaccinees, whereas 20% of placebos developed 366 
spontaneously anti-Tat Abs (all immunogenicity population evaluated). Anti-Tat Ab responses 367 
detected in vaccinees and placebos were significantly different (Chi-Square test, p<0.0001, both for 368 
total Abs and Ig subclasses). In particular, 81% of vaccinees developed anti-Tat B-clade IgM, 96% 369 
IgG, and 76% IgA, as opposed to 10% IgM, 13% IgG, and 6% IgA of placebos, respectively 370 
(Figure 2A). As shown in Table 4 and Figure 2B, 69% of vaccinees developed anti-Tat Abs of all Ig 371 
subclasses, 28% developed one or two Ig subclasses, and 3% of vaccinees had no detectable anti-372 
Tat Abs. In contrast, 1% of placebos developed anti-Tat Abs of all three Ig subclasses, 19% of one 373 
or two subclasses, and 80% had no detectable anti-Tat Abs (Chi-Square test, p< 0.0001, Figure 2B). 374 
Anti-Tat B-clade Ab mean titers peaked between week 8 and week 12 for all Ig subclasses and 375 
statistically significant differences for IgG titers between vaccinees and placebos were observed 376 
since week 12 (weeks 12-24, p <0.0001; week 48 p=0.0004) (Figure 2C). Moreover, anti-Tat Ab 377 
responses persisted significantly longer in vaccinees as compared to placebos (Log-Rank test, 378 
p=0.0019) (Figure 3A). Further, Ab persistence was longer in vaccinees and placebos with 2 or 3 379 
Ab subclasses as compared to those with 1 subclass (Figure 3B and C). The “Per Protocol” analysis 380 
confirmed the results from the immunogenicity population, in particular, 88/91 (97%) and 20/96 381 
(21%) of vaccinees and placebos, respectively, developed anti-Tat Abs (p<0.0001). 382 
  383 
Vaccination with the HIV-1 B-clade Tat protein elicits Abs also recognizing Tat from A, C and D 384 
clades. The presence of anti-Tat Abs against clades other than B (i.e. C, D, A) was evaluated in the 385 
99 vaccinees. Fifty-one patients that were negative at baseline also for Abs against Tat from A, C, 386 
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or D clade, after immunization with the B-clade Tat protein developed anti-Tat Abs recognizing Tat 387 
from one or more of these other clades (Table 5), in addition to Tat B clade. 388 
At baseline (Figure 4A), 29 vaccinees, although negative for anti-Tat Abs against B-clade Tat, had 389 
Abs against Tat of one or more of the other clades tested (76% C clade, 41% A clade, 14% D 390 
clade). After vaccination, all of them experienced a statistically significant increase of intensity of 391 
these responses (Figure 4B). In particular, changes of intensity from baseline levels were similar for 392 
IgM and IgA for all clades, while for IgG changes were higher for C and D clades. 393 
 394 
Vaccination with the HIV-1 B-clade Tat protein induces cross-clade neutralizing anti-Tat Abs. The 395 
neutralization of  B-clade Tat-mediated entry of oligomeric B-clade Env in DC was used to 396 
investigate anti-Tat Ab functional activity in 24 participants. This assay permits measuring HIV 397 
neutralization even in the presence of cART (57, 65), which interferes with traditional infection 398 
assays (77). At baseline, entry of Env in the absence of Tat was comparable for all sera (Figure 5A, 399 
left panel) and did not change after immunization (Figure 5A, right panel). As shown previously 400 
(57), Tat increased entry of Env with all sera prior to immunization (baseline) (Figure 5B, left 401 
panel), whereas sera from vaccinees strongly reduced Env entry (more than 60%) (week 20 and 48, 402 
p<0.0001). This occurred to a lesser extent also with sera from anti-Tat Ab-positive placebos (about 403 
37% reduction) (Figure 5B, right panel). No changes were observed in Ab-negative placebos 404 
(Figure 5B, right panel). Differences between vaccinees and anti-Tat Ab-negative placebos were 405 
statistically significant at both time points examined (week 20 and week 48 p=0.0009 and 406 
p=0.0003, respectively). Further, differences in reaching 50% neutralization (ND50) of Env entry 407 
were observed between vaccinees (11/13, 85%) and the anti-Tat Ab-positive placebos (2/6, 33%) 408 
(Fisher's Exact Test, p=0.0460). Neutralization of Tat-mediated Env entry in DC was also analyzed 409 
for C clade Tat and Env. As shown in Figure 6, anti-Tat Abs elicited by vaccination with the B-410 
clade Tat protein induced cross-clade neutralizing Abs against B and C clade Tat/Env complex 411 
entry in DC (p<0.0001 for both clades).  412 
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 413 
Anti-Tat but not anti-Env Abs correlate with neutralization of Env entry in vaccinees. To evaluate 414 
the role of both anti-Tat and anti-Env humoral responses on the neutralization of Tat-mediated entry 415 
of oligomeric Env in DC, anti-Env Abs were also tested (all immunogenicity population evaluated). 416 
At baseline, all subjects had anti-Env Abs (geometric mean Ab-titers 72,408, range 200-409,600) 417 
with titers that did not change significantly during the follow-up (data not shown) and correlated 418 
positively with the levels of Tat-mediated Env entry in DC (r=0.42, p=0.0214) indicating lack of 419 
neutralization. In contrast, after immunization, vaccinees showed a significant inverse relationship 420 
between anti-Tat IgM or IgG Ab titers (p= 0.0853 and p= 0.0039, respectively) or anti-Env IgG 421 
titers (p=0.0015) and the levels of Tat-mediated Env entry in DC (Table 6), indicating correlation 422 
with neutralization of Env entry. Of note, anti-Env Ab titers did not correlate with neutralization of 423 
Env entry in anti-Tat Ab-negative placebos, indicating that anti-Env Abs require anti-Tat Abs to 424 
inhibit the Tat/Env complex formation and virus entry, as shown earlier both in vitro and in vivo 425 
(65, 70, 78). 426 
 427 
Tat vaccination induces CD4+ T cell number increases, which correlate with neutralization. 428 
Compared to placebos, CD4+ T-cell counts increased significantly and progressively in vaccinees 429 
(Figure 7) up to week 24 when they peaked (mean gain of 60 cells/µL p=0.0015), whereas at the 430 
end of the study (week 48) the mean gain compared to baseline values was of 28 cells/µL. In 431 
contrast, placebos showed a slower kinetics and lower, and not statistically significant, increases 432 
(mean gain of 11 cells/µL), which peaked at 48 weeks with a mean value of 17 cells/µL as 433 
compared to baseline. CD4+ T-cell counts were also analyzed by treatment groups over time by 434 
applying a random-effect regression model. The increase from baseline of CD4+ T cells up to week 435 
24 was 2.2 cells/µL (95% CI 1.1; 3.2, p<0.0001) per week in vaccinees and 0.1 cells/µL (95% CI 436 
0.7; 3.4) per week in the placebo group, respectively. The difference between the coefficients of 437 
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regression was statistically significant (p=0.0031). The comparison between the two arms showed 438 
statistically significant changes from baseline at week 20 (p=0.0466) and week 24 (p=0.0250).  439 
To evaluate the effect of vaccination on the increase of CD4+ T cells according to their levels at 440 
study entry, baseline values were stratified by quartiles. Increases up to about 90 cells/µL were 441 
detected in vaccinated subjects in Q1, Q2, and Q3, while no significant changes were observed in 442 
Q4, indicating that vaccination had major effects in subjects with lower CD4+ T cell number at 443 
baseline (Figure 8). Placebos showed significant CD4+ T-cell increases only in Q1 (up to 84 444 
cells/µL). Of note, the gaining in CD4+ T-cell counts in Q1 was lower (up to 58 cells/µL) in 445 
placebos negative for anti-Tat Abs, who also experienced a significant CD4+ T-cell decay in Q3 at 446 
week 20 (Figure 8). 447 
Further, CD4+ T-cell increases correlated significantly with neutralization of Env entry in DC in 448 
vaccinees (n= 19) (p=0.0023) as compared to placebos (n=11) (Table 7).  449 
 450 
Tat vaccination maintains CD4+ T cells and contains viral load rebound in patients non-compliant 451 
to therapy. Compliance was always verified at each study visit. However, despite counseling for 452 
adherence to therapy, medical records showed poor compliance (i.e. missing doses up to prolonged 453 
interruptions) in 24 volunteers, particularly between week  20 and 48 after the first immunization. 454 
Of them, 18 were vaccinees and 6 were placebos (1 anti-Tat Ab-positive and 5 anti-Tat Ab-455 
negative). None of the vaccinees non-compliant to cART therapy experienced a decay of CD4+ T 456 
cells which, instead, increased above study entry levels (median increase of 50 cells/µL at week 16, 457 
p= 0.0814, 57 cells/µL at week 20, p= 0.0987 and 30 cells/µL at week 48, as compared to baseline). 458 
In contrast, the anti-Tat Ab-negative placebos had CD4+ T-cell decreases below study entry levels 459 
(median of -33 cells/µL at week 12, p=0.0625 and -60 cells/µL at week 48 versus baseline levels). 460 
Comparison between vaccinees and anti-Tat Ab negative placebos showed significant differences at 461 
week 8 and week 12 (p=0.0859 and p=0.0336, respectively) (Fig. 9). 462 
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With regard to viral load, plasma viremia remained undetectable at week 48 in 12/18 (67%) 463 
vaccinees, and in 3/5 (60%) of anti-Tat Ab-negative placebos. In addition, in patients with 464 
detectable viral load at week 48, the geometric mean levels were lower in vaccinees (1,090 465 
copies/mL), as compared to anti-Tat Ab-negative placebos (3,179 copies/mL) (Fig. 10).  466 
 467 
Discussion 468 
The development of therapeutic vaccination strategies for treating people already infected with 469 
HIV-1 has been recently accelerated, with an increasing number of vaccine candidates being tested 470 
in clinical trials, either in drug-naïve patients or in association with cART. In drug-naïve patients, 471 
therapeutic vaccines are expected to contain infection (i.e., low to undetectable plasma viral load 472 
and CD4+ T cell preservation), preventing progression to disease as well as virus transmission, 473 
while in cART-treated patients therapeutic vaccination is expected to intensify the efficacy of 474 
cART, thus supporting a more effective immune restoration and virological control, particularly in 475 
poor immunological responders or cART non-compliant patients, preventing progression to AIDS-476 
related as well as non AIDS-related diseases and virus transmission. 477 
No therapeutic vaccines are currently market approved. However, the rapidly expanding HIV/AIDS 478 
therapeutic vaccine field portraits a variety of approaches, which differ sensibly in many aspects, 479 
the most relevant being the antigen chosen (unlike preventative vaccines, regulatory and accessory 480 
genes are frequently targeted; in some cases almost the entire HIV genome is targeted), and the 481 
delivery systems, which range from simple subcutaneous, intradermal, or intramuscular vaccine 482 
administration to reinfusion of autologous DCs loaded ex vivo with the selected antigen(s) (9, 79-483 
89). In most vaccine trials conducted in treated patients cART therapy was interrupted to assess the 484 
potency of the immunological control of infection provided by vaccination, while they were not 485 
aimed at evaluating the immunological recovery, with the exclusion of CD4+ T cell counts, which, 486 
however, did not appear to go beyond the restoration provided by cART alone (9, 79).  487 
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Our approach has focused on Tat, a key HIV virulence factor, which is released extracellularly in a 488 
biologically active form also under cART, and promotes virus reactivation, replication and 489 
spreading while inducing immune activation and disabling the host immune defense (reviewed in 490 
25). Thus, induction of effective anti-Tat Abs may represent a pathogenesis-driven therapeutic 491 
intervention to block disease progression as indicated by the effects of long-lasting, high titers anti-492 
Tat Abs in natural infection (9, 79) or after vaccination with Tat, which induced CD4+ T cell 493 
recovery, immune restoration, as well as reduction of immunoactivation and of proviral DNA in 494 
Italian subjects (ISS T-002 trial) (57). 495 
The results of the present study indicate that B-clade Tat immunization is safe and well tolerated 496 
also in South African individuals infected with a different virus subtype. Further, vaccination 497 
induced anti-Tat Abs in almost all vaccinees. Abs were durable, at high titers and of multiple 498 
subclasses. Remarkably, B-clade Tat vaccination induced cross-clade (A, C, D) Tat-binding Abs, 499 
which were capable of neutralizing Tat-mediated entry in DC of oligomeric HIV Env from B and C 500 
clade, suggesting that the B-clade Tat protein used in our vaccine program may be used for a cross-501 
clade HIV vaccine approach.  502 
A natural humoral anti-Tat Ab response developed in a small number of placebos, a finding 503 
expected from previous studies conducted in Italy and South Africa (53, 54, 69, 70). Indeed, as 504 
compared to the  other HIV proteins which elicit Abs  virtually in all infected patients, production 505 
of anti-Tat Abs is seen only in about 20% of the HIV-infected subjects present in all cohorts we 506 
have investigated. Surprisingly, although Tat is released extracellularly, only a small percentage of 507 
individuals recognizes and mounts an Ab response against this protein. One reason could be its 508 
molecular mimicry for extracellular matrix proteins such as fibronectin (FN) and vitronectin (VN) 509 
(90-92). As for Tat, FN and VN possess a similar basic region and RGD sequence binding to the 510 
α5β1, αVβ3 and αVβ5 integrins (93, 94). 511 
In vaccinees, neutralization correlated positively with anti-Tat IgM and IgG Ab titers, whereas Env 512 
entry was not neutralized by anti-Env Abs in the absence of anti-Tat Abs (57, 65). Indeed, anti-Env 513 
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Abs measured prior to immunization both in vaccinees and placebos had a positive correlation with 514 
increased levels of Tat-mediated Env entry in DC. This reproduces what has been seen earlier with 515 
sera from Italian vaccinees (ISS T-002 trial) or in monkey studies (65). In particular, by forming a 516 
complex with Env, Tat increases virus entry in DC and blocks neutralization by anti-Env Abs, 517 
which is restored and further increased only in the presence of anti-Tat Abs (65). 518 
Tat vaccination was associated with significant increases of CD4+ T cells above baseline levels, 519 
whereas placebos showed a slower kinetics and lower, and not statistically significant, increases, as 520 
expected in individuals on cART for a mean of about 3 years. Increases of CD4+ T cells in 521 
vaccinees correlated significantly with neutralization. Of note, CD4+ T cells increased particularly 522 
in vaccinees with lower CD4+ T cell counts at baseline. This is of particular relevance since poor 523 
immunological response to therapy is frequent either in patients starting cART late, even if 524 
virologically suppressed (4-8), or in patients with persistent immune activation (95-99) or low 525 
compliant (100-103). A poor CD4+ T cell recovery (˂500 T cells/μl) is associated with disease 526 
progression, co-morbidities, hospitalization and death (104-107). These patients are those that most 527 
require ART intensification. 528 
While in the ISS T-002 trial conducted in Italy patients were highly compliant to therapy, 529 
compliance was lower in the ISS T-003 study, a finding particularly frequent in Southern Africa 530 
where scarce adherence to cART therapy represents a relevant clinical problem since it is associated 531 
with disease progression, virus drug resistance and transmission (108-111). Of interest, none of the 532 
vaccinees non-compliant to cART therapy experienced a decay of CD4+ T cells, and in most of 533 
them plasma viremia remained undetectable at week 48 while, in those with detectable viremia, 534 
viral load levels were low. In contrast, the anti-Tat Ab-negative placebos had CD4+ T-cell decreases 535 
below entry levels, and in most of them plasma viremia rebounded to geometric mean levels higher 536 
than those recorded in non-compliant vaccinees. Although these results are only descriptive, since 537 
the groups are too small to draw any firm conclusion, they indicate the need of ad hoc studies to 538 
address whether cART intensification by Tat  therapeutic immunization may mitigate the effects of 539 
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low adherence to therapy. To this end, structured therapy interruption studies after cART 540 
intensification by the Tat vaccine are being planned.  541 
The results of the ISS T-003 trial are highly consistent with those of the ISS T-002 (53, 57), 542 
although the two trials were conducted in individuals with different genetic background, infected 543 
with HIV from different subtypes (B versus C clade), and on cART for different periods of time 544 
(i.e., mean of 6 years in the ISS T-002 trial versus about 3 years in the ISS T-003 trial). Indeed, 545 
safety and immunogenicity results were remarkably similar, sometimes identical, as were the CD4+ 546 
T-cell increments, particularly in subjects with lower levels at baseline (53, 57), suggesting that 547 
poor immunological responders to therapy could greatly benefit from Tat immunotherapy. 548 
The results from the Italian trial (ISS T-002) clearly indicate that proviral DNA reduction (as 549 
opposed to CD4+ T cell increase) is a late event, particularly under NNRTI-based drug regimens 550 
requiring 108 weeks for detecting a significant proviral reduction (57). Indeed, no significant 551 
reductions of proviral DNA are seen at week 48 in both (ISS T-002 and ISS T-003) trials (data not 552 
shown). Furthermore, it appears that time on effective cART is also relevant, in that proviral DNA 553 
decay plateau after about 4-5 years of successful therapy (112, 113). Thus, unlike the Italian trial in 554 
which vaccinees had been on therapy on average for 6 years, subjects enrolled in the South African 555 
study had been on cART for around 3 years. Altogether these data indicate that longer periods of 556 
time are required to see an effect on proviral DNA in NNRTI-treated South African subjects, which 557 
represent 97% of the trial population.  558 
Therefore, similarly to the ISS T-002 trial, a roll-over observational study (ISS T-003 EF-UP) has 559 
been initiated for the South African trial to ensure the extended follow-up of the volunteers, in order 560 
to evaluate the persistence of vaccine-induced immune responses as well as the immunological and 561 
virological effects of Tat immunization. In particular, proviral DNA will be monitored to verify 562 
whether Tat vaccination is capable of reducing it, as observed for the ISS T-002 trial after 3 years 563 
from vaccination (57). 564 
 565 
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Conclusions 566 
These data indicate that immunization with B clade Tat induced functionally effective cross-clade 567 
anti-Tat Abs and CD4+ T-cell increases and reinforce the notion that B clade Tat is a suitable 568 
candidate for therapeutic immunization against different HIV clades in different geographical areas, 569 
thus supporting the future conduct of phase III studies in South Africa.  570 
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Table 1. Baseline characteristics of study participants  1072 
 n Vaccinees n Placebo 
Gender 
Male 
Female 
 
32 
68 
 
32.0% 
68.0% 
 
20 
80 
 
20.0% 
80.0% 
Race     
Black 100 100.0% 99 99.0% 
Caucasian 0 0.0% 0 0.0% 
Mixed 0 0.0% 1 1.0% 
Age 
Mean  s.d.a 
Range 
 
100 
 
36.1  5.6 
21.1-45.8 
 
100 
 
36.0  6.2 
19.6-45.4 
CD4+ (cells/l) 
Mean  s.d. 
Range 
 
99 
 
510  229 
137-1530 
 
100 
 
563  195 
242-1252 
CD4+ (%) 
Mean  s.d. 
Range 
 
99 
 
28 8 
7-49 
 
100 
 
29  7 
17-42 
HIV RNA (copies/mL)     
<40 (assay cut-off) 94 95.0% 96 96.0% 
≥ 40 5 5.0% 4 4.0% 
Years from HIV 
diagnosis  
 
 
 
 
Mean  s.d. 
Range 
100 5.0  3.0 
1.0-14.0 
100 4.9  3.3 
1.0-19.0 
Years from cART 
initiation 
 
 
 
 
Mean  s.d. 
Range 
100 3.5  2.0 
0.7-8.2 
100 3.3  2.1 
0.6-8.9 
cART regimen  
NNRTI or NRTI-based  
PI-based 
 
97 
3 
 
97.0% 
3.0% 
 
98 
2 
 
98.0% 
2.0% 
Previous Tuberculosis 29 29.0% 34 34.0% 
n indicates the number of individuals; aStandard deviation 1073 
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Table 2. Total adverse events observed in study participants reported by relationship to study drug and intensity 1074 
 Treatment group  
 Tat vaccine Placebo Total 
     n  (m)    %      n (m)     %     n (m)    % 
Number of subjects in safety population 100   100   200   
          
Number of subjects with at least one 
adverse event 
96 (883) 96.0 94 (581) 94.0 190 (1464) 95.0 
          
Relationship with study medication          
 Certain 72 (541) 72.0 59 (250) 59.0 131 (791) 65.5 
 Probable 14 (35) 14.0 23 (38) 23.0 37 (73) 18.5 
 Possible 25 (45) 25.0 28 (56) 28.0 53 (101) 26.5 
 Unlikely 41 (80) 41.0 37 (63) 37.0 78 (143) 39.0 
 Not related 76 (182) 76.0 74 (174) 74.0 150 (356) 75.0 
 Not assessable 0 (0)  0 (0)  0 (0)  
 Not known 0 (0)  0 (0)  0 (0)  
          
Intensity          
 Mild 94 (774) 94.0 91 (522) 91.0 185 (1296) 92.5 
 Moderate 42 (90) 42.0 28 (48) 28.0 70 (138) 35.0 
 Severe 15 (17) 15.0 9 (10) 9.0 24 (27) 12.0 
 Not applicable 1 (1) 1.0 0 (0)  1 (1) 0.5 
 Not known 1 (1) 1.0 1 (1) 1.0 2 (2) 1.0 
          
Serious adverse events  6 (8) 6.0 2 (2) 2.0 8 (10) 4.0 
 Related 0 (0) 0.0 0 (0) 0.0 0 (0) 0.0 
 Not related 6 (8) 6.0 2 (2) 2.0 8 (10) 4.0 
_________________________________________________________________________________________________________________ 
n=number of subjects, (m)=number of mentions, %=all percentages are expressed as the percentage of the number of subjects in the safety 
population in each treatment group. 
 1075 
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Table 3. Incidence of related adverse events by system organ class and relationship to study treatment 1076 
 Treatment group  
 Tat vaccine Placebo  
MedDRA system organ class Related¹ Not related² Related¹ Not related² Total 
  n (m) %  n (m)   % n (m)   % n (m)  % n (m)  % 
Number of subjects 100   100   100   100   200   
                
Number of subjects with at least one adverse event 77 (621) 77.0 85 (262) 85.0 72 (344) 72.0 81 (237) 81.0 190 (1464) 95.0 
General disorders and administration site conditions 73 (520) 73.0 8 (10) 8.0 58 (199) 58.0 11 (12) 11.0 133 (741) 66.5 
Infections and infestations 1 (1) 1.0 50 (77) 50.0 2 (2) 2.0 56 (88) 56.0 107 (168) 53.5 
Nervous system disorders 27 (40) 27.0 19 (24) 19.0 38 (67) 38.0 10 (13) 10.0 81 (144) 40.5 
Musculoskeletal and connective tissue disorders 16 (25) 16.0 14 (16) 14.0 17 (31) 17.0 15 (28) 15.0 54 (100) 27.0 
Gastrointestinal disorders 9 (12) 9.0 20 (25) 20.0 14 (18) 14.0 13 (19) 13.0 49 (74) 24.5 
Skin and subcutaneous tissue disorders 10 (12) 10.0 15 (15) 15.0 10 (18) 10.0 13 (16) 13.0 47 (61) 23.5 
Reproductive system and breast disorders 0 (0)  22 (24) 22.0 0 (0)  22 (27) 22.0 44 (51) 22.0 
Investigations 2 (3) 2.0 19 (28) 19.0 2 (2) 2.0 8 (10) 8.0 30 (43) 15.0 
Blood and lymphatic system disorders 7 (7) 7.0 7 (9) 7.0 5 (6) 5.0 3 (3) 3.0 21 (25) 10.5 
Injury, poisoning and procedural complications 0 (0)  10 (12) 10.0 0 (0)  5 (7) 5.0 15 (19) 7.5 
Vascular disorders 1 (1) 1.0 6 (6) 6.0 0 (0)  3 (3) 3.0 10 (10) 5.0 
Respiratory, thoracic and mediastinal disorders 0 (0)  2 (2) 2.0 0 (0)  4 (5) 4.0 6 (7) 3.0 
Eye disorders 0 (0)  3 (3) 3.0 0 (0)  2 (2) 2.0 5 (5) 2.5 
Metabolism and nutrition disorders 0 (0)  3 (3) 3.0 0 (0)  1 (1) 1.0 4 (4) 2.0 
Renal and urinary disorders 0 (0)  2 (2) 2.0 0 (0)  1 (1) 1.0 3 (3) 1.5 
Surgical and medical procedures 0 (0)  2 (2) 2.0 0 (0)  1 (1) 1.0 3 (3) 1.5 
Psychiatric disorders 0 (0)  2 (4) 2.0 0 (0)  0 (0)  2 (4) 1.0 
Cardiac disorders 0 (0)  0 (0)  1 (1) 1.0 0 (0)  1 (1) 0.5 
Immune system disorders 0 (0)  0 (0)  0 (0)  1 (1) 1.0 1 (1) 0.5 
___________________________________________________________________________________________________________________________ 
n= number of subjects, (m)= number of mentions, %= all percentages are expressed as the percentage of subjects in the safety population in each 
treatment group. Adverse event data were coded using the MedDRA dictionary version 15.0. 
¹ Related refers to events whose relationship to the study treatment was regarded as certain, probable or possible. 
² Not related refers to events whose relationship to the study treatment was regarded as unrelated or unlikely related. 
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Table 4. Anti-Tat Ab response by Ig subclasses in vaccinees and placebos 
 Vaccinees (n = 99) Placebos (n = 100) 
 n Percentage n Percentage 
IgM+ 1 1.0 5 5.0 
IgG+ 9 9.1 5 5.0 
IgA+ 0 0.0 2 2.0 
IgM+IgG+ 11 11.1 4 4.0 
IgM+IgA+ 0 0.0 0 0.0 
IgG+IgA+ 7 7.1 3 3.0 
IgM+IgG+IgA+ 68 68.7 1 1.0 
Ab-negative 3 3.0 80 80.0 
n indicates the number of subjects. Percentage of subjects positive for 1, 2 or 3 anti-Tat Ab 
subclasses at any given time point after the first immunization 
 
Table 5. Induction of anti-Tat cross-clade Abs after immunization in vaccinees negative at 
baseline for any anti-Tat Abs 
HIV Clades n % 
C 5 9.8 
D 7 13.7 
A 4 7.8 
C+D 12 23.5 
C+A 1 2.0 
D+A 7 13.7 
C+D+A 15 29.4 
Total 51 100.0 
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Sera from 51 vaccinees negative at baseline also for anti-Tat Abs against C, D and A clades were 
tested between week 12 and week 24 (99 tested) after immunization with the B-clade Tat protein. 
All patients mounted anti-Tat Ab responses against A, C, and/or D clade. 
 
Table 6. Relationship between anti-Tat or anti-Env Ab titers and Tat-mediated Env entry in 
DC in vaccinees  
aConfidence interval. A longitudinal analysis for repeated measures by generalized estimating 
equation method was used for the analysis. Vaccinees anti-Tat Ab-positive n=19 (86 observations), 
Placebos anti-Tat Ab-negative n=5 (30 observations). 
 
Table 7. Longitudinal analysis of Tat-mediated Env entry in DC versus CD4+ T-cell counts 
Treatment  Estimate 95% CIa p-value 
Vaccinees -127 -208 -45 0.0023 
Placebo -72 -194 51 0.2515 
aConfidence interval. A significant inverse relationship was observed between CD4+ T cells and the 
Tat-mediated Env entry in DC in the presence of sera from vaccinees (n=19) but not from placebo 
(n=11) indicating a positive relationship of CD4+ T-cell increases with neutralization of Env entry 
Parameter Estimate 95% CIa p-value 
Vaccinees     
anti-Tat IgM (log10 titers) -0.15 -0.31 0.02 0.0853 
anti-Tat IgG (log10 titers) -0.12 -0.20 -0.04 0.0039 
anti-Tat IgA (log10 titers) -0.02 -0.12 0.08 0.7579 
anti-Env IgG (log10 titers) -0.06 -0.09 -0.02 0.0015 
Placebos      
anti-Env IgG (log10 titers) 0.00 -0.02 0.02 0.9471 
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in DC. A longitudinal analysis for repeated measures by generalized estimating equation method 
was used for the analysis. 
 
Figure Legends 
Figure 1. CONSORT flow diagram. The number of participants screened, enrolled, randomized, 
followed-up and analyzed is shown for vaccine and placebo groups. Two hundred participants were 
randomised to one of the two treatment groups and analyzed for safety (safety population). One 
subject who received only one immunization was excluded from the immunogenicity population 
(Total = 199). Thirteen volunteers were excluded from the “Per protocol” analysis: 4 received less 
than three immunizations, 4 did not complete three or more visits of follow-up and 5 had major 
protocol non-compliance (Total = 187). 
Figure 2. Anti-Tat humoral immune response elicited in study participants. (A) Percentage of 
responders for anti-Tat Abs (see Methods) in vaccinees (n=99) or placebos (n=100). The absolute 
number of vaccines/placebos developing anti-Tat Ig subclasses are reported on the top of each 
histogram. Statistical significant differences were detected between vaccinees and placebos for each 
Ig and for total response (p<0.0001, Chi-Square test). (B) Percentage of responders for anti-Tat Abs 
stratified according to the presence of one or more Ab isotype in vaccinees (n=99) or placebos 
(n=100). The absolute number of vaccines/placebos developing one or more Ab isotype are 
reported on the top of each histogram. Statistical significant differences were detected between 
vaccinees and placebos (p<0.0001, Chi-Square test). (C) IgM, IgG and IgA Ab mean titers (with 
standard error) in responders (vaccinees: n=79 for IgM, n=95 for IgG and n=75 for IgA; placebos: 
n=9 for IgM, n=12 for IgG and n=6 for IgA). Significant differences were detected between 
vaccinees and placebos for anti-Tat IgG Abs from week 12 to week 48 (Student’s t-test). 
Figure 3. Anti-Tat Ab durability in responders. (A) Kaplan-Meier estimates showing the 
cumulative probability of anti-Tat Ab durability during follow-up in responders (see Methods) 
(vaccinees: n=96; placebos: n=18). Anti-Tat Abs persisted significantly longer in vaccinees as 
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compared to the placebo group (p=0.0019, Log-Rank test). (B) Kaplan-Meier estimates showing the 
cumulative probability of anti-Tat Ab durability during follow-up in vaccinees (left panel) or 
placebo (right panel) responders, according to the number of anti-Tat Ab isotypes (vaccinees: 1 
subclass n=10, 2 or 3 subclasses n=86; placebo: 1 subclass n=10, 2 or 3 subclasses n=8). 
Figure 4. Increase of cross-clades anti-Tat Abs elicited in vaccinees. (A) baseline OD values of 
anti-Tat IgM, IgG and IgA against clades C, D and A in vaccinees prior to immunization (n=29, 
76% C clade, 41%  A clade, 14% D clade). (B) Changes from baseline of IgM, IgG and IgA Ab 
responses (OD) against Tat from other clades (C, D and A) after vaccination. Testing was 
performed at the peak of Ab responses (between 12 and 24 weeks). Statistical analysis was 
performed using the Wilcoxon signed-rank test. P-values assess the increase from baseline.  
Figure 5. Neutralization of Tat/Env complex entry in DC. Baseline values (left panels) and 
changes from baseline after immunization (right panels) of B-clade Env entry in DC in the absence 
(A) or presence (B) of B-clade Tat in anti-Tat Ab-positive (n=13) vaccinees, and anti-Tat Ab-
positive (n=6) or anti-Tat Ab-negative (n=5) placebos at week 20 and 48 from the first 
immunization. Reduction of Env entry in DC by sera indicates neutralization. Student’s t-test was 
applied to evaluate the changes from baseline within and between treatment groups. 
Figure 6. Neutralization of B- and C-clade Tat/Env complex entry in DC in vaccinees. 
Neutralization of B- (n=13) and C- (n=10) clade Env entry in DC in the presence or absence of (B- 
or C-clade) Tat by sera of Ab-positive vaccinees, measured at week 20 or week 48 after 
immunization. Data are presented as mean values with standard errors. Student's t-test for paired 
data was used for the analyses. 
Figure 7. Changes from baseline of CD4+ T-cell number in vaccinees and placebos. Baseline 
values (left panel) and changes from baseline (right panel) of CD4+ T-cell counts in vaccinees 
(n=99) and placebos (n=100). Data are presented as mean values with standard errors. Longitudinal 
analysis for repeated measures by the generalized estimating equations method was applied for the 
analysis. P-values assess the changes from baseline within and between treatment groups.  
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Figure 8. CD4+ T-cell numbers up to week 48 in vaccinees and placebo stratified by quartiles 
according to baseline values. Baseline values (left panels) and changes from baseline (right 
panels) of CD4+ T cells in (A) vaccinees (n=98), (B) placebo (n=100) and (C) anti-Tat Ab-negative 
placebo (n=80). Data are presented as mean values with standard errors. Longitudinal analysis for 
repeated measures was used. P-values assess the changes from baseline within each treatment 
group.  
Figure 9. Changes from baseline of CD4+ T-cell number in vaccinees and placebos non 
compliant to therapy. Baseline values (left panel) and changes from baseline after immunization 
(right panel) of CD4+ T-cell counts in vaccinees (n=18) and placebos (n=5). Data are presented as 
box plots. Wilcoxon signed rank sum test for paired data and Wilcoxon-Mann-Whitney test were 
used for the analyses. P-values assess the changes from baseline within and between treatment 
groups.  
Figure 10. Plasma viremia up to week 48 in vaccinees and placebo non compliant to therapy. 
Percentage of vaccinees and anti-Tat Ab-negative placebos non-compliant to cART with detectable 
plasma viremia (upper panel), and plasma viremia values (log10 copies/mL) in patients with 
detectable viral load at each study visit (lower panel).  
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Legends to Supplementary Figures 
Supplementary  Figure 1. B, C, A and D Tat clades sequences and GeneBank accession numbers. 
Based on data published in Hemelaar J et al (AIDS 2011, 2:679-689), which refer to the time period 
2004-2007, a frequency of 0.98%, 27.28%, 11.54%, and 3.61% for HIV-1 subtypes B, C, A and D, 
respectively, was calculated for the African continent. 
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